Last reviewed · How we verify
Microarray patch B
At a glance
| Generic name | Microarray patch B |
|---|---|
| Also known as | Calcipotriol, Betamethasone dipropionate |
| Sponsor | LEO Pharma |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Clinical Trial to Assess Safety, Tolerability and the Pharmacodynamics Effect of Calcipotriol/Betamethasone Dipropionate in a New Administration Form in Subjects With Chronic Plaque Psoriasis. (PHASE1)
- Hepatitis B Vaccine Delivered Trans-dermally by MAP (PHASE1)
- Study of Tumor Tissue Samples From Patients With Stage I, Stage II, or Stage III Malignant Melanoma
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Microarray patch B CI brief — competitive landscape report
- Microarray patch B updates RSS · CI watch RSS
- LEO Pharma portfolio CI